695 Topical application of KPI-150, a potent inhibitor of Kv1.3 channels on effector memory T cells, demonstrates preclinical efficacy in atopic dermatitis model

ShK toxin: history, structure and therapeutic applications for autoimmune diseases

“…Most infiltrating T-cells in skin lesions from patients with moderate-to-severe atopic dermatitis (AD) express high levels of Kv1.3, suggesting that inhibitors of Kv1.3 may be effective in treating AD. [72] Ovalbumininduced delayed type hypersensitivity and oxazoloneinduced dermatitis are considered to be models of atopic dermatitis. [ [81] while a topical formulation of ShK-198 was effective in treating oxazolone-induced dermatitis.…”

“…[ [81] while a topical formulation of ShK-198 was effective in treating oxazolone-induced dermatitis. [72] Even where compensation by KCa3.1 channels was reported to over-ride KV1.3 block, ShK administered alone suppressed delayed type hypersensitivity significantly in 2 of 3 studies, albeit modestly. [49]…”